Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

ABSTRACT: Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti-cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop resistance to the first-, second-, and third-generation drugs. To explore alternatives to such whack-a-mole strategies, we simulated in patient-derived xenograft models the situation of patients receiving first-line TKIs. Monotherapies comprising approved 1st-line TKIs were compared to combinations with antibodies specific to EGFR and HER2. We observed uniform and strong superiority of all drug combinations over the respective monotherapies. Prolonged treatments, high TKI dose and specificity were ess

SUBMITTER: Dr. Ilaria Marrocco 

PROVIDER: S-SCDT-EMM-2020-13144 | biostudies-other |

REPOSITORIES: biostudies-other